Seed Round · €2.2M · Open

Detect sepsis 5–8 hours before the body signals collapse.

SepsIgnite is the world's first patented theranostic platform: ultra-early detection paired with a first-in-class treatment that targets the sepsis cascade at its source.

Book an Investor Call Learn more →
1.1M
deaths per year, US & Europe
The #1 cause of preventable in-hospital death
NONE
approved drug targets the cascade
40 years of failed attempts. All suppressed, none redirected.
€34B
therapeutic market, uncontested
No direct competitor in the theranostic space
0.5%
of US GDP in annual healthcare costs
Sepsis is the single largest driver of hospital expenditure
US Pat. 11,224,633 · EU filing in progress
Preclinical proof of concept achieved
Positioning for €10–15M Series A in 24 months
Founded by Dr. Xavier Forceville, MD, PhD, EMBA
The Problem

Sepsis kills in hours. Diagnosis takes days.

The clinical trajectory is unforgiving: infection becomes sepsis, sepsis becomes septic shock, septic shock becomes organ failure — all within hours. Yet the diagnostic gold standard, blood culture, takes 24 to 72 hours to return a result.

And even when caught in time, there is nothing to give. No approved treatment targets the cascade itself. Forty years of trials, billions spent — every approach tried to suppress the immune response. Every one failed.

24–72h
Time to diagnosis with current methods
While organ systems are failing in real time.
45%
Mortality rate in septic shock
Even in fully equipped ICUs with optimal supportive care.
0 drugs
Approved to treat the sepsis cascade
Consequences are managed. The cause remains untreated.
Our Approach

Work with the body's response, not against it.

Every failed drug tried to oppose the immune response. SepsIgnite redirects it. Two integrated programs, one clinical insight.

01 / Detect

5–8 hours of advance warning

Our proprietary biomarker signature identifies sepsis onset before clinical signs appear. Point-of-care compatible, lab-integrable. Defined CE & FDA pathway.

02 / Treat

First-in-class cascade intervention

Selenoprotein-P infusion + ultra-rapid sodium selenite. Regulates hyperactivated white blood cells and protects vessel wall integrity. No drug has ever done this. We have preclinical proof it works.

03 / Integrate

Theranostic: diagnostic + therapeutic, one system

The diagnostic creates the treatment indication. The treatment validates the diagnostic. Together, they form a proprietary care pathway and a defensible commercial moat, protected by foundational patents.

Track Record

Built on 40 years of research. Protected by patents.

This is not a hypothesis. The science is established, the IP is secured, and the preclinical signal is clear.

600+

Animals studied

Small & large, across 3 leading European centers

3+

Peer-reviewed publications

In leading biochemical journals, incl. Antioxidants & Redox Signaling 2021 & 2022

01

Phase II RCT completed

Multicenter randomised controlled trial, Meaux/Rennes

01

Patent granted

US Pat. 11,224,633 · EU prosecution in progress

Founder's Story

Why 30 years on one problem.

Dr. Xavier Forceville

"Sepsis is a tragedy far more common than people realize. Patients leave the ICU without understanding what happened to them, and spend months recovering from something they were never told they had.

For over 70 years, since the birth of intensive care, we have been managing the consequences of this cascade without treating its cause. Intensive care can halve mortality. But survivors still face the post-sepsis syndrome. The cascade itself remains untouched.

What I found, through 30 years of work grounded in 80 years of fundamental biochemistry, is a radically different path. I am convinced it can transform sepsis: from a syndrome we endure, into a disease we detect early and treat at its source."

The Opportunity

A €34B market with no incumbent theranostic player.

Diagnostic · OECD
45M tests/yr · CE + FDA pathway
€780M
Therapeutic · OECD
1.9M sepsis shock + ARDS/yr
€34B
Defense & NATO preparedness
Non-dilutive funding pathway
Additive

The sepsis therapeutics market is vast, growing, and entirely unserved at the cascade level. No company has combined a companion diagnostic with a cascade-targeting therapeutic. SepsIgnite is positioned to own this category.

Beyond the clinical market, a NATO-identified strategic gap in combat trauma and mass-casualty preparedness extends our reach and unlocks non-dilutive defense funding pathways.

"The current €2.2M raise delivers a defined 24-month package: diagnostic validation data + therapeutic safety package, positioning SepsIgnite for a €10–15M Series A."
The Team

Built by clinicians. Guided by experts.

SepsIgnite is founded by the researchers who have spent their careers studying this exact problem: 30 years of sepsis research, a 9-member Scientific Committee, and a European translational partnership network already in place.

Dr. Xavier Forceville
CEO & CSO
MD, PhD, EMBA (HEC). Former Head of Critical Care. 30 years of sepsis pre-clinical studies and clinical trial translation, anchored in 80 years of fundamental quantum biochemistry.
Ms. Dalila Belkhiri
Chief Business Officer
[Bio to be completed.]
Dr. Daniel Lueschner
CMC Director
PhD Biochemistry. 15 years GMP & regulatory expertise. Leads the recombinant production pathway for Selenoprotein-P.
Ms. Marine Provoyeur
Chief Marketing Officer
15 years across Medtech, marketing, public relations and pricing strategy. Leads brand positioning and go-to-market strategy for SepsIgnite's commercial launch.
M. Nathaniel Harari
Head of IT & Digital
IT & Digital infrastructure, GDPR compliance, and NATO cybersecurity standards. Leads the technical architecture and data security framework for SepsIgnite's digital platform.
Scientific Committee
9 Members
Led by Prof. D. Annane (Head of Critical Care, APHP Saclay), Gen. Y. Chancerelle (Military Health Service) and Prof. P. Van Antwerpen (ULB Brussels). Intensivists, pharmacologists and methodologists across Europe.

Full Scientific Advisory Board and clinical partner network available on request under NDA.

Ready to talk?

We're raising €2.2M to unlock 24 months of value creation. Materials are available under NDA.

Book an Investor Call

Or reach us directly at inquiries@sepsignite.com

SepsIgnite · Confidential · EBAN 2026 · All materials subject to NDA

Scientific Literature

Peer-reviewed. Independently validated.

SepsIgnite's platform is grounded in 30 years of published research across biochemistry, critical care, and translational medicine.

01
Forceville X. et al. Selenium and Selenoprotein-P in sepsis: biological rationale and therapeutic targets. Antioxidants & Redox Signaling, 2021.
Peer-reviewed
02
Forceville X. et al. Ultra-rapid sodium selenite and Selenoprotein-P infusion: first-in-class cascade intervention in experimental sepsis. Antioxidants & Redox Signaling, 2022.
Peer-reviewed
03
Preclinical study: combined Selenoprotein-P infusion and ultra-rapid selenite injection in resuscitated septic rats. Normalised lactate, no observed toxicity at therapeutic dose. ENVA Veterinary University, Paris, 2015.
Preclinical
04
Microcirculation study validating endothelial protection mechanism of the SepsIgnite therapeutic approach. Charité University Hospital, Berlin.
Translational
05
Large-animal (sheep) study confirming preclinical signal at scale. Université Libre de Bruxelles (ULB), Brussels.
Preclinical
06
Phase II multicenter randomised controlled trial. Primary endpoint data available under NDA. CHU Meaux / CHU Rennes.
Clinical · Phase II RCT
07
5 lectures presented at international critical care and biochemistry congresses, including ESICM and SRLF. Principal investigator: Dr. Xavier Forceville.
Congress presentations
08
US Patent No. 11,224,633 — Theranostic platform combining Selenoprotein-P biomarker and therapeutic selenium formulation. EU prosecution in progress.
IP · Granted

Full bibliography, clinical data package, and methodology notes are available to qualified investors under NDA. Contact us via the form above.